AbbVie Inc.
ABBV Healthcare Drug Manufacturers - General NYSE
$226.08
$-2.63 (-1.15%)
Open: $228.93 | High: $229.25 | Low: $225.05 | Prev Close: $228.71
Market Cap: $399.53B
Volume: 3.6M | Avg: 6.0M
Last updated: December 05, 2025 at 10:00 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 405
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 172.58 |
| P/B Ratio | -151.63 |
| P/S Ratio | 6.70 |
| EPS | $1.31 |
| Beta | 0.35 |
| Shares Outstanding | 1.77B |
| 52-Week High | $244.81 |
| 52-Week Low | $164.39 |
| SMA 50 | $227.96 |
| SMA 200 | $204.50 |
| Dividend Yield | 3.06% |
| Annual Dividend | $6.92 |
| Next Earnings | February 04, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 76.2% |
| Operating Margin | 21.8% |
| Net Margin | 4.0% |
| ROE | 498.8% |
| ROA | 1.8% |
| Debt/Equity | -26.02 |
| Current Ratio | 0.72 |
| Quick Ratio | 0.60 |
Balance Sheet
| Total Assets | $135.16B |
| Total Liabilities | $131.80B |
| Total Equity | $3.33B |
| Cash | $5.52B |
| Total Debt | $67.84B |
| Net Debt | $62.32B |
Income Statement
| Revenue | $56.33B |
| Gross Profit | $39.43B |
| Operating Income | $9.14B |
| Net Income | $4.28B |
| EBITDA | $14.91B |
| Revenue/Share | $33.66 |
Cash Flow
| Operating CF | $18.81B |
| CapEx | $974.00M |
| Free Cash Flow | $17.83B |
| Book Value/Share | $-1.47 |
| Tangible Book/Share | $-52.22 |
| Equity/Share | $-1.49 |
Technical Indicators
| RSI (14) | 45.17 Neutral |
| MACD |
0.68
Signal: 1.09
|
| Volatility | 27.95% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +14.56% |
| Sharpe Ratio | 0.58 Fair |
| Volatility (Ann.) | 27.07% Moderate |
| ABBV (1Y) | +14.56% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +2.7% |
Sector Comparison (Healthcare)
| Metric | ABBV | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 172.58 | 28.77 | 97% |
| P/B Ratio | -151.63 | 2.01 | 0% |
| ROE (%) | 498.75% | 1.51% | 98% |
| Net Margin (%) | 4.01% | 10.15% | 23% |
| Stock Score | 405 | 506.0 | 8% |
| 1Y Return (%) | +14.56% | +4.25% | 71% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | $226.08 | $227.23 | $228.14 | $230.12 | $227.96 | $204.50 | 45.17 | 0.68 | 27.95% | 3733100 | Neutral | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the ABBV stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| ABBV | Could Buying AbbVie Today Set You Up for Life? | Neutral | fool.com | Read More |
| ABBV | How Strong Is AbbVie's Immunology Franchise After Humira's LOE? | Neutral | zacks.com | Read More |
| ABBV | Groupe la Francaise Purchases 6,466 Shares of AbbVie Inc. $ABBV | Neutral | defenseworld.net | Read More |
| ABBV | AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | Neutral | zacks.com | Read More |
Company Information
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| CEO | Robert A. Michael |
| Employees | 55000 |
| Country | US |
| IPO Date | 2013-01-02 |
| Exchange | NYSE |
| Website | https://www.abbvie.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category